Clinical Trial Update: A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib [Phase 2]

View source ↗

Summary

Phase 2b study of the oncolytic vaccinia virus Pexa-Vec (JX-594) in patients with advanced hepatocellular carcinoma after sorafenib failure has completed. The u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pexa-Vec (JX-594) (recombinant vaccinia virus)

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Status: COMPLETED